Correspondence 0001193125-25-052682 from TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc.
Date: March 12, 2025 · CIK: 0001783328 · Accession: 0001193125-25-052682
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285570
Letter
Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-285570) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), TScan Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement be accelerated to March 14, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Finnbarr Murphy of Goodwin Procter LLP at (212) 459-7257.
TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 March 12, 2025 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Sincerely,
TScan Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 March 12, 2025 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-285570) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), TScan Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement be accelerated to March 14, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Finnbarr Murphy of Goodwin Procter LLP at (212) 459-7257. Sincerely, TScan Therapeutics, Inc. /s/ Jason Amello Name: Jason Amello Title: Chief Financial Officer Cc: Finnbarr Murphy, Esq., Goodwin Procter LLP